[
  {
    "question": "Direct question, what is the best drug to treat hypnic headache?",
    "option_a": "Lithium",
    "option_b": "Lamotrigine",
    "option_c": "Propranolol",
    "option_d": "Triptan",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hypnic headache is a rare primary headache that predominantly occurs during sleep and typically awakens patients from sleep. It generally affects older individuals and is characterized by its timing rather than by specific associated symptoms. The exact mechanism is not fully delineated, but hypothalamic dysfunction is suspected to play a key role, leading to disruption of the sleep cycle and the circadian regulation of pain. Lithium\u2019s efficacy is thought to relate to its effects on circadian rhythms and neuronal excitability. Patients present with headaches that typically occur only at night or early in the morning, frequently awakening them from sleep. The headache is usually bilateral and dull, lasting from minutes to hours. These features help distinguish hypnic headache from cluster headache or migraine, which have other distinguishing characteristics. The diagnosis is based on clinical history and the temporal pattern of the headache. Differential diagnoses include obstructive sleep apnea (which may cause morning headaches), cluster headache (which typically has a different frequency and unilateral distribution), and migraine. A careful history regarding the timing and quality of the headache is essential. First-line treatments generally include lifestyle modifications and the use of caffeine at bedtime, given its benign side-effect profile. Lithium is widely recognized as an effective prophylactic treatment when caffeine is inadequate or contraindicated. However, lithium monitoring is required given its narrow therapeutic index. In pregnant or lactating women, lithium carries teratogenic concerns, especially during the first trimester, and its use in these populations necessitates careful risk-benefit analysis; alternative treatments (such as avoiding the condition-inducing triggers or using caffeine) might be preferred. Option A (Lithium) is appropriate among the provided choices as it has established efficacy in prophylaxis for hypnic headache. Option B (Lamotrigine) and Option C (Propranolol) are not considered standard treatments for hypnic headache, and Option D (Triptan) is typically used for migraine abortive therapy rather than in hypnic headache. 1. Hypnic headache is known as the \u201calarm clock headache\u201d because it often awakens patients from sleep. 2. Caffeine at bedtime is a common and simple first-line treatment. 3. Lithium is used for prophylaxis but requires close monitoring due to its side-effect profile. Current research supports the use of both caffeine and lithium as effective treatments. There is an increasing body of case series that validate low-dose lithium\u2019s efficacy in reducing headache frequency and severity in patients with hypnic headache.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the main neurotransmitter in migraine headache?",
    "option_a": "Glutamate",
    "option_b": "Serotonin",
    "option_c": "Dopamine",
    "option_d": "GABA",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine is a complex neurovascular primary headache disorder. Although the precise pathogenesis remains multifactorial, serotonin (5-HT) has long been recognized as a central neurotransmitter in its development, particularly influencing vascular tone and nociceptive modulation. Migraine involves activation of the trigeminovascular system with subsequent release of vasoactive peptides, leading to neurogenic inflammation and vasodilation. Serotonin plays a crucial role, as evidenced by the efficacy of triptans, which are 5-HT1B/1D receptor agonists that counteract vasodilation and inhibit peptide release. Altered serotonin metabolism has been extensively documented in migraine sufferers. Patients often experience pulsatile, unilateral headache with associated symptoms such as nausea, photophobia, and phonophobia. The role of serotonin is highlighted by the rapid relief provided by triptans during acute attacks. Other neurotransmitters (glutamate, dopamine, and GABA) are also implicated but do not hold as central a role as serotonin in classic migraine pathophysiology. The diagnosis of migraine is clinical, based upon patient history and meeting criteria outlined in the ICHD. Differential diagnoses include tension-type headache, cluster headache, and secondary headache disorders. History of associated symptoms like nausea, aura, and photophobia help differentiate migraine from other headache types. Acute management typically involves NSAIDs and triptans, while preventive treatments may include beta-blockers, antiepileptics, or antidepressants. In pregnancy and lactation, first-line abortive therapy is usually acetaminophen, and limited data support cautious use of sumatriptan if clearly indicated. Non-pharmacologic measures and trigger avoidance are important adjuncts. Option A (Glutamate) is involved in excitatory neurotransmission and may contribute to cortical spreading depression, but it is not considered the main neurotransmitter in migraine. Option B (Serotonin) is central to migraine pathophysiology and is the primary target for abortive therapies such as triptans. Option C (Dopamine) has been implicated in the prodrome and may play a role in associated emesis, but it is not the primary neurotransmitter. Option D (GABA) is inhibitory and has a lesser direct role in the pathogenesis of migraine. 1. Triptans work by activating 5-HT1 receptors, mitigating the neurovascular cascade in migraines. 2. Serotonin modulation remains a cornerstone of acute migraine therapy. 3. While migraine is multifactorial, serotonin is the most validated neurotransmitter in its development. Recent research continues to underscore the role of serotonin in migraine, even as newer treatments targeting CGRP are emerging. However, the serotonergic mechanism remains fundamental, and triptans continue to be widely recommended in clinical practice based on extensive evidence.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant lady in 8th month, presented with disabling migraine attack that needs acute abortive therapy. What would you give her?",
    "option_a": "Oxycodone",
    "option_b": "Triptan",
    "option_c": "Ibuprofen",
    "option_d": "Dihydroergotamine",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Management of acute migraine attacks in pregnancy requires careful consideration of both maternal and fetal safety. Migraines are neurovascular headaches, and abortive therapies must balance efficacy with safety, especially in the later stages of pregnancy. Migraine involves activation of the trigeminovascular system and release of vasoactive neuropeptides leading to inflammation and pain. In pregnancy, hormonal changes can affect the frequency and intensity of migraine attacks, and the choice of abortive therapy is influenced by its effect on uteroplacental blood flow and fetal development. A pregnant woman in her 8th month with a disabling migraine needs effective and rapid pain relief. The use of certain abortive therapies (such as NSAIDs) can be harmful in the third trimester, and others (like ergot derivatives) are contraindicated due to their potent vasoconstrictive effects on the uterus. The evaluation of headache in pregnancy necessitates ruling out secondary causes such as preeclampsia, cerebral venous thrombosis, or other neurological emergencies. A detailed history and appropriate laboratory or imaging studies, if indicated, help in confirming that the headache is indeed a migraine attack. First-line therapy for mild to moderate migraine in pregnancy is acetaminophen. However, in cases of disabling migraine that do not respond to acetaminophen, sumatriptan (a triptan) is considered the abortive drug of choice because of its relatively favorable safety profile in pregnancy. NSAIDs like ibuprofen are avoided in the third trimester due to the risk of premature closure of the ductus arteriosus. Opioids (e.g., oxycodone) carry risks of dependence and neonatal withdrawal, and ergot derivatives (e.g., dihydroergotamine) are contraindicated because they can induce uterine contractions. Pregnancy and lactation considerations require that any abortive therapy be used at the lowest effective dose and for the shortest duration possible, with careful monitoring. Option A (Oxycodone) is generally avoided due to the risk of maternal dependency and neonatal withdrawal. Option B (Triptan), specifically sumatriptan, has the most supportive safety data in pregnancy for aborting severe migraine attacks when acetaminophen is inadequate. Option C (Ibuprofen) is contraindicated in the third trimester because of fetal cardiovascular risks. Option D (Dihydroergotamine) is contraindicated due to its potent vasoconstrictive properties which can compromise uterine blood flow. 1. Sumatriptan has the most safety data among triptans for use in pregnancy, particularly in the second and third trimesters. 2. Always rule out secondary causes of headache in pregnant patients. 3. Avoid NSAIDs in the third trimester due to risks of premature ductal closure. Recent studies and meta-analyses have reinforced the relative safety of sumatriptan in pregnancy, with no significant increase in adverse fetal outcomes when used in appropriate doses. Guidelines from headache societies and obstetric associations now support its cautious use when clearly indicated, highlighting that its benefits in disabling migraine may outweigh potential risks.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "WOTF presents in visual aura of migraine and not in occipital aura seizures?",
    "option_a": "Duration less than 1 minute",
    "option_b": "Colored objects",
    "option_c": "Scintillating scotoma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine with aura is a primary headache disorder that often presents with transient neurological symptoms preceding or accompanying the headache. One common visual aura is the scintillating scotoma, characterized by a shimmering or flickering blind spot that gradually expands. The underlying mechanism in migraine aura is believed to be cortical spreading depression\u2014a wave of neuronal and glial depolarization followed by suppression of brain activity. In contrast, occipital seizures result from brief, paroxysmal epileptiform discharges in the occipital cortex, typically producing visual symptoms that are shorter in duration and may have a different quality. Patients with migraine aura experience a gradual onset of visual disturbances such as scintillating scotomas that typically evolve over several minutes and then resolve. Occipital seizures, on the other hand, present with very brief, abrupt visual phenomena that often last less than one minute and may consist of simple flashes or colored lights. Diagnosis is primarily clinical. Detailed symptom history distinguishes migraine aura (lasting 5 to 20 minutes, with gradual spread) from occipital seizures (lasting seconds to less than a minute). Differential diagnoses include transient ischemic attacks and other visual disturbances, and in some cases, an EEG or MRI may be warranted for clarity. Acute migraine management involves symptomatic treatment using NSAIDs, triptans, or a combination approach. Prophylactic treatments may be considered in patients with frequent attacks. Pregnancy and lactation considerations are critical: oxygen, acetaminophen, and certain NSAIDs (in the first two trimesters) are generally safer, while triptans require careful risk\u2010benefit analysis according to the latest guidelines. Occipital seizures require antiepileptic drugs, often after confirmation by EEG. Option A (Duration less than 1 minute) is more suggestive of occipital seizures, not migraine aura. Option B (Colored objects) may occur in various visual phenomena but is not the classic description for migraine aura. Option C (Scintillating scotoma) precisely describes the visual phenomenon typical of migraine aura. Option D is not provided. Hence, Option C is the correct answer. 1. Scintillating scotoma is pathognomonic for migraine aura. 2. Migraine aura visual phenomena typically develop gradually and last 5\u201320 minutes. 3. Occipital seizures have a much shorter duration (<1 minute) and are often associated with other epileptic manifestations. Recent studies continue to support the role of cortical spreading depression in initiating migraine aura. Current ICHD-3 criteria emphasize using the detailed time course and evolution of visual symptoms to differentiate migraine aura from other conditions such as occipital lobe seizures.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "30 years old male came to the clinic with one month history of headache with typical description of cluster type. Asked what is the best next step to manage him?",
    "option_a": "High flow O2",
    "option_b": "SC sumatriptan",
    "option_c": "Calcium channel blocker",
    "option_d": "Reassurance",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a severe, unilateral headache disorder characterized by bouts or clusters of attacks with prominent ipsilateral autonomic features such as lacrimation, nasal congestion, or ptosis. It is believed that hypothalamic activation triggers a cascade involving the trigeminal autonomic reflex, leading to the intense pain and associated autonomic symptoms. The circadian periodicity of cluster headache attacks further supports the central role of the hypothalamus. Patients typically describe excruciating, unilateral periorbital or temporal pain, with attacks lasting 15 to 180 minutes. The abrupt onset and short duration necessitate rapid abortive treatment. Autonomic features help differentiate cluster headache from other headache types. The diagnosis is clinical and based on the attack pattern, severity, and associated autonomic signs. Differential diagnoses include migraine (which usually lasts longer and is less strictly unilateral) and paroxysmal hemicrania (which has shorter attack duration but also has a response to indomethacin). Acute management: High-flow oxygen (100% via a non-rebreather mask at 12-15 L/min) is the first-line therapy and is safe for use in pregnant and lactating women. Subcutaneous sumatriptan is a second-line option if oxygen is unavailable or ineffective. Preventive therapy includes agents like verapamil. In pregnancy, oxygen remains the safest acute treatment, and caution is advised with triptans and other medications. Option A (High flow O2) is the first-line immediate treatment for an acute cluster headache attack. Option B (SC sumatriptan) is an effective alternative but is generally considered second-line if oxygen is not available. Option C (Calcium channel blocker) is used for prophylaxis rather than acute treatment. Option D (Reassurance) is inappropriate given the severity of the condition. 1. High-flow oxygen is the fastest acting and safest acute abortive treatment for cluster headache. 2. Cluster headaches have a distinct circadian pattern. 3. Preventive therapy, such as verapamil, is essential to reduce attack frequency. Recent guidelines from neurological societies endorse high-flow oxygen as the first-line treatment for acute cluster headache attacks and emphasize the importance of differentiating cluster headache from other primary headache disorders for appropriate management.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "29 years old female came to the clinic asking 3rd opinion for her headache. First doctor told her she has cluster headache while the other one said it is SUNCT. She asked you what is the best way to differentiate these 2 headaches?",
    "option_a": "Response to the treatment",
    "option_b": "Duration of attack",
    "option_c": "Imaging",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is a rare primary headache disorder within the group of trigeminal autonomic cephalalgias, which can be confused with cluster headache due to overlapping features. SUNCT is thought to arise from abnormal activation in the posterior hypothalamus and trigeminal pathways, leading to very brief, frequent headache attacks. The pathophysiology is distinct from cluster headache primarily in the duration and frequency of the attacks. SUNCT attacks are characterized by their brevity, typically lasting between 5 and 240 seconds, and occur with high frequency throughout the day. Cluster headache attacks, however, typically last 15 to 180 minutes. This difference in duration is a key clinical differentiator. The diagnostic approach involves careful patient history with emphasis on the timing and duration of attacks. Differential diagnoses include cluster headache, paroxysmal hemicrania, and other TACs (trigeminal autonomic cephalalgias). The short duration of SUNCT attacks is the most distinguishing feature. Treatment of SUNCT can be challenging; options include antiepileptic medications like lamotrigine or even intravenous lidocaine in severe cases. In contrast, cluster headache is managed acutely with oxygen and triptans, with preventive measures like verapamil. For pregnant or lactating women, medication choices must be carefully weighed for safety, often favoring non-pharmacologic options where possible. Option A (Response to the treatment) is less useful diagnostically because different treatments may have variable efficacy. Option B (Duration of attack) is the best differentiator since SUNCT attacks are markedly shorter than those of cluster headache. Option C (Imaging) is typically unremarkable in both conditions and does not aid in their differentiation. Option D is not provided. 1. The duration of headache attacks is a critical clue in differentiating SUNCT from cluster headache. 2. SUNCT attacks are extremely brief but highly frequent. 3. A detailed headache history is essential for the correct diagnosis of trigeminal autonomic cephalalgias. Recent research continues to emphasize the differentiation of trigeminal autonomic cephalalgias based on attack duration and frequency. Updated guidelines stress the importance of these temporal features in guiding both diagnosis and treatment strategies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Typical scenario of migraine without aura, moderate to severe attacks, \u03c0?",
    "option_a": "Codeine + caffeine",
    "option_b": "NSAID",
    "option_c": "Triptan",
    "option_d": "is absent.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine without aura is a common primary headache disorder characterized by moderate to severe headache pain, often accompanied by nausea, vomiting, photophobia, and phonophobia. It does not have the transient neurological symptoms that define migraine with aura. The pathogenesis involves a complex interplay between neurovascular dysregulation, activation of the trigeminovascular system, and the release of vasoactive peptides. Triptans, which act as selective serotonin 5-HT1B/1D receptor agonists, help to abort the cascade by causing cranial vasoconstriction and inhibiting the release of inflammatory neuropeptides. Patients typically experience unilateral or bilateral pulsatile headache of moderate to severe intensity that worsens with physical activity. Triptans are especially useful when the headache is moderate to severe and unresponsive to simpler analgesics. The diagnosis is based on clinical criteria per the ICHD-3. The differential includes tension-type headache (which is typically milder and non-pulsatile) and other primary headache disorders. A careful history is essential to confirm the diagnosis and rule out secondary causes. For acute abortive treatment, mild migraine attacks may be managed with NSAIDs, but moderate to severe attacks are best treated with triptans. First-line treatment for moderate to severe migraine attacks in non-pregnant adults is a triptan. In pregnancy, NSAIDs are to be avoided in the third trimester and caution is advised with triptans, though some (like sumatriptan) may be considered if the benefits outweigh the risks. Lactating mothers should also use these medications cautiously with a risk-benefit analysis. Option A (Codeine + caffeine) is not the preferred choice due to concerns over opioid use and the risk of medication overuse headache. Option B (NSAID) might be adequate for mild attacks but may fall short in moderate to severe cases. Option C (Triptan) is the recommended first-line therapy for moderate to severe migraine attacks as per current guidelines. Option D is absent. 1. Early treatment with triptans can prevent progression of a migraine attack. 2. Migraine without aura is the most common form of migraine. 3. Avoid opioid-based therapies to reduce the risk of medication overuse headache. Contemporary guidelines from the American Headache Society and other bodies confirm the effectiveness of triptans for moderate to severe migraine attacks while cautioning about the use of opioids. Research continues to explore alternative therapies and preventive strategies, especially for patients with frequent or refractory migraines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "A 30-year-old female patient known case of migraine presented with new headache unlike her migraine for more than 3 months. It is more constant, not associated with nausea, vomiting, photophobia or phonophobia, not improved with usual analgesics.\nWhich of the following is the most likely diagnosis?",
    "option_a": "Chronic migraine headache.",
    "option_b": "Medications overuse headache.",
    "option_c": "New daily persistent headache.",
    "option_d": "Tension headache.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "New Daily Persistent Headache (NDPH) is a primary headache disorder characterized by the abrupt onset of a daily and unremitting headache that persists for longer than three months. It is distinct from other headache types because it starts suddenly in patients who may have had previous headache disorders (such as migraine) but now experience a new, different headache pattern. The exact mechanism behind NDPH is not fully understood, though hypotheses include persistent activation of central pain pathways or a post-infectious inflammatory process. There may be a component of central sensitization and dysregulation within the trigeminovascular system. Ongoing research continues to evaluate potential triggers, such as viral illnesses or stressful events. Clinically, patients with NDPH report a daily headache with a continuous nature that does not typically exhibit the pulsatile quality of migraine. In contrast to migraine, these headaches lack associated nausea, vomiting, photophobia, or phonophobia. The headache is generally resistant to the patient\u2019s usual abortive therapies, which can serve as a clinical clue in differentiating it from a typical migraine recurrence. The diagnosis of NDPH is clinical, based on history and duration. Differential diagnoses include chronic migraine (which maintains migrainous features), tension-type headache (usually not as constant or unremitting), medication overuse headache (which is associated with frequent analgesic use), and secondary causes of chronic headache. Brain imaging (usually MRI) is recommended if red flags are present or to exclude secondary pathology. Management of NDPH can be challenging due to its refractory nature. Initial treatment strategies include a trial of preventive medications such as amitriptyline, topiramate, or other neuromodulators. Some patients benefit from therapies targeting central sensitization such as nerve blocks or neuromodulatory techniques. In pregnancy and lactation, agents with better safety profiles (such as low-dose amitriptyline) may be preferred, and non-pharmacological therapies (e.g., cognitive behavioral therapy, relaxation techniques) should be considered. A: Chronic migraine typically retains migrainous features and episodic attacks before becoming chronic. B: Medication overuse headache is associated with frequent use of headache medications causing rebound pain. D: Tension-type headache is usually bilateral and pressure-like, not a new persistent headache. C (New daily persistent headache) is correct as it best fits the clinical description of a constant, new headache without migrainous features. 1. NDPH is characterized by a sudden onset of a daily, unremitting headache that persists for more than 3 months. 2. The absence of typical migrainous features (nausea, photophobia, etc.) helps differentiate it from chronic migraine. 3. Always consider secondary causes in new, persistent headaches by reviewing the patient\u2019s history and appropriate imaging if indicated. Recent studies continue to explore the pathogenesis of NDPH, with ongoing research into anti-inflammatory and neuromodulatory treatments. Clinical guidelines remain focused on symptomatic and preventive management, with an emphasis on individualized treatment plans particularly in special populations such as pregnant or lactating patients.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A patient came with history of severe unilateral headache, last less than 5 minutes, stabbing in nature, associated with tearing and conjunctival injection.\nWhich of the following is the best treatment for him?",
    "option_a": "Indomethacin",
    "option_b": "Lamotrigine",
    "option_c": "Carbamazepine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This clinical scenario is suggestive of a short-lasting trigeminal autonomic cephalalgia, specifically a form of SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing). SUNCT is characterized by brief, severe headaches with prominent autonomic features. SUNCT is thought to be due to dysfunction within the posterior hypothalamus and trigeminal autonomic reflexes. Abnormal activation of these pathways likely contributes to the brief, stabbing pain and associated autonomic symptoms such as tearing and conjunctival injection. Current evidence hints at sodium channel dysfunctions which is why medications that stabilize neuronal membranes can be effective. Patients with SUNCT experience very short, sharp, unilateral headache attacks that last from seconds up to a few minutes, with high frequency over the day. The presence of prominent cranial autonomic symptoms (tearing, conjunctival injection) helps to distinguish it from other headache syndromes such as cluster headache or paroxysmal hemicrania. The diagnosis is primarily clinical. Differential diagnoses include paroxysmal hemicrania (which typically lasts longer, 2-30 minutes, and responds completely to indomethacin), trigeminal neuralgia (which lacks autonomic features), and cluster headache (which lasts 15-180 minutes). A detailed headache history is key, and neuroimaging is often warranted to exclude secondary causes. First-line management for SUNCT involves lamotrigine, which is used due to its action on sodium channels and ability to stabilize neuronal firing. Second-line therapies may include other anticonvulsants, and in some refractory cases, intravenous lidocaine has been employed. During pregnancy and lactation, the choice of anticonvulsants must consider teratogenic risks; lamotrigine is generally considered relatively safe compared to others, but close monitoring and risk-benefit analysis are necessary. A: Indomethacin is the treatment of choice for paroxysmal hemicrania, not SUNCT. C: Carbamazepine is primarily used in trigeminal neuralgia and is less effective in SUNCT. B: Lamotrigine is correct because it is considered first-line therapy for SUNCT due to its effect on voltage-gated sodium channels and documented efficacy in reducing attack frequency and intensity. 1. SUNCT is characterized by very short, frequent, stabbing attacks with prominent autonomic symptoms. 2. Lamotrigine is the preferred treatment due to its sodium channel stabilization properties. 3. Differentiating between TACs often hinges on attack duration and response to specific medications like indomethacin. Recent guidelines and studies support the use of lamotrigine as a first-line agent for SUNCT, with emerging research into other neuromodulatory therapies. Ongoing trials focus on optimizing dosing and evaluating long-term outcomes, particularly in special populations including women of childbearing age.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young female patient known case of migraine controlled on medications. Now she presented with unilateral headache, associated with lacrimation and conjunctival injection, lasted for less than 2 minutes then resolved. It occurs up to 40 times per day and she is completely asymptomatic between the attacks.\nWhich of the followings is the most likely diagnosis?",
    "option_a": "Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)",
    "option_b": "Chronic paroxysmal hemicrania",
    "option_c": "Hemicrania continua",
    "option_d": "Cluster headache",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The scenario describes a young female with very brief unilateral headache attacks (lasting less than 2 minutes), with lacrimation and conjunctival injection, occurring up to 40 times per day. These features are prototypical of SUNCT \u2013 a specific type of short-lasting unilateral neuralgiform headache with cranial autonomic features. SUNCT is associated with hyperexcitability in the trigeminal-autonomic reflex pathways. Abnormal neuronal firing, particularly involving sodium channel dysregulation and potential hypothalamic dysfunction, leads to the characteristic sudden, intense pain episodes accompanied by autonomic phenomena. New insights suggest a complex interplay between peripheral triggers and central modulation. The extremely short duration of attacks (less than 2 minutes) and the high frequency (up to 40 attacks per day) along with clear autonomic signs (lacrimation, conjunctival injection) are hallmark features of SUNCT, distinguishing it from related conditions. While chronic paroxysmal hemicrania has some overlapping features, its attacks typically last longer (2-30 minutes) and respond dramatically to indomethacin. Diagnosis of SUNCT is clinical. The differential includes chronic paroxysmal hemicrania (differentiated by longer attack duration and indomethacin response), cluster headache (which has longer duration and distinct circadian periodicity), and hemicrania continua (a continuous unilateral headache with superimposed exacerbations). A thorough history and headache diary are key, and neuroimaging is typically performed to rule out secondary causes. Management typically involves preventive medications, with lamotrigine considered the first-line agent. In cases refractory to medication, other anticonvulsants or neuromodulatory strategies may be considered. In pregnant or lactating patients, lamotrigine is one of the relatively safer anticonvulsants, though dose adjustments and close monitoring are essential. A: Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) is correct given the brief attack duration and autonomic features. B: Chronic paroxysmal hemicrania, while similar, has longer attack durations (2\u201330 minutes) and requires indomethacin responsiveness. C: Hemicrania continua is characterized by a continuous unilateral headache rather than discrete brief attacks. D: Cluster headache typically lasts 15\u2013180 minutes with distinct circadian periodicity. 1. SUNCT attacks are extremely brief but can occur very frequently throughout the day. 2. The presence of lacrimation and conjunctival injection are key autonomic features that aid diagnosis. 3. Differentiating SUNCT from paroxysmal hemicrania is largely dependent on the duration of the headaches and response to medication. Current research continues to explore the efficacy of lamotrigine in SUNCT and the underlying neurophysiological mechanisms of TACs. Updated guidelines emphasize individualized treatment plans and caution regarding medication choices in women of childbearing age due to teratogenic risks.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 29-year-old female came to the neurology clinic asking for third opinion for headache. The first physician told her that she has cluster headache while the second physician told her that she has SUNCT headache.\nWhat is the best way to differentiate between these two headache types?",
    "option_a": "Response to treatment",
    "option_b": "Duration of the attack",
    "option_c": "Brain imaging",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "The scenario presents a diagnostic dilemma between cluster headache and SUNCT. Both are types of trigeminal autonomic cephalalgias but have distinguishing features. The key aspect to focus on is the duration of the headache attacks, which is fundamental in differentiating these conditions. Both cluster headaches and SUNCT involve activation of the trigeminal-autonomic reflex, with the hypothalamus playing a central role. However, the patterns of neuronal activation and the duration of the pain episodes differ, reflecting variations in underlying ion channel activity and neural network involvement. Cluster headache attacks typically last between 15 and 180 minutes and occur in circadian patterns, while SUNCT attacks are very short (lasting seconds to a few minutes) and can occur with a much higher frequency throughout the day. These distinctions are essential in clinical diagnosis, as they guide the therapeutic approach. The primary method of differentiating cluster headache from SUNCT is by detailed headache history focusing on attack duration. Differential diagnoses include other trigeminal autonomic cephalalgias such as paroxysmal hemicrania (which lasts 2\u201330 minutes and is indomethacin-responsive) and SUNA. Neuroimaging is generally normal in both conditions and is mainly used to exclude secondary causes. Management differs significantly between these conditions. For cluster headaches, oxygen therapy and subcutaneous sumatriptan are effective abortive treatments, with verapamil commonly used as a preventive agent. For SUNCT, first-line management is lamotrigine. In pregnancy and lactation, treatment decisions must weigh the benefits and risks; both verapamil and lamotrigine have been used cautiously with appropriate monitoring, but non-pharmacological approaches may also be considered. A: Response to treatment is useful but is not the most immediate differentiator as both may have overlapping treatment responses. B: Duration of the attack is correct since cluster headaches typically last much longer (15\u2013180 minutes) compared to SUNCT (seconds to minutes). C: Brain imaging is generally normal in both conditions and does not help differentiate them. Thus, option B is the best answer. 1. Attack duration is the most distinguishing factor between SUNCT (lasting seconds to a few minutes) and cluster headache (lasting 15\u2013180 minutes). 2. Both conditions are classified as trigeminal autonomic cephalalgias but require different management strategies. 3. Always obtain a thorough headache history to aid in accurate diagnosis. Recent updates in headache classification and management guidelines reinforce the importance of attack duration in differentiating TACs. Emerging research is exploring novel treatment modalities for both cluster headache and SUNCT, as well as their safety profiles in special populations such as pregnant or lactating women.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "2nd line management of trigeminal N after carbamazepine.",
    "option_a": "Pregabalin",
    "option_b": "Lamotrigine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a neuropathic pain disorder characterized by sudden, paroxysmal, shock\u2010like pains affecting one or more divisions of the trigeminal nerve. Carbamazepine is the established first\u2010line treatment, and when patients do not tolerate or respond to it, a second\u2010line agent is considered. The prevailing theory is that vascular compression at the trigeminal nerve root entry zone leads to focal demyelination. This causes ectopic generation and cross\u2010talk of nerve impulses, producing the classic paroxysmal pain. Alternative agents such as lamotrigine may stabilize neuronal membranes by inhibiting voltage-sensitive sodium channels. Patients typically present with unilateral, lancinating, brief episodes of facial pain triggered by activities (e.g., chewing, brushing teeth). When carbamazepine is not effective or tolerated due to side effects, options such as lamotrigine are considered based on their favorable side effect profile and mechanism. The diagnosis is clinical. Differential diagnoses include atypical facial pain, dental pathology, and multiple sclerosis-associated trigeminal neuralgia. MRI is commonly employed to rule out secondary causes, such as mass lesions or vascular malformations. First-line therapy is carbamazepine, titrated to effect. For patients who fail or cannot tolerate carbamazepine, second-line options include oxcarbazepine, lamotrigine, gabapentin, or baclofen. In pregnancy or lactation, both the teratogenic potential and the impact on nursing infants must be considered; lamotrigine is generally considered safer than many antiepileptics but still requires monitoring and specialist consultation. Option A (Pregabalin) is used for neuropathic pain but lacks robust evidence as a second-line agent in trigeminal neuralgia. Option B (Lamotrigine) has evidence supporting its utility after carbamazepine failure, making it the correct second-line choice. Options C and D were not provided. 1. Trigeminal neuralgia is often described as one of the most severe pains known. 2. A careful medication history is essential since many antiepileptics are used off-label for neuropathic pain. 3. Always consider imaging to exclude secondary causes in atypical presentations. Recent reviews and clinical guidelines support the use of lamotrigine as a viable second-line therapy when carbamazepine is ineffective or not tolerated. Ongoing research is evaluating other agents and interventional procedures for refractory cases.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Migraine without aura, most relevant clinical picture.",
    "option_a": "30 to 60 minute in duration",
    "option_b": "Throbbing quality",
    "option_c": "Bilateral location",
    "option_d": "Not aggravated by daily activity",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine without aura is a primary headache disorder characterized by recurrent episodes of moderate-to-severe headache often with a throbbing or pulsatile quality and associated features such as photophobia, phonophobia, and nausea. Migraine is now understood as a neurovascular disorder, involving cortical spreading depression, brainstem activation, and trigeminovascular system sensitization, leading to the release of vasoactive neuropeptides that cause inflammation and pain. Patients typically report unilateral, pulsating headache that lasts from 4 to 72 hours if untreated, with worsening on physical activity. The throbbing quality is a classical description, differentiating migraine from tension-type headache, which is typically pressing or tightening. The clinical diagnosis is made using criteria set by the International Classification of Headache Disorders. Differential diagnoses include tension-type headache (which is usually bilateral and less severe) and cluster headache (which is shorter in duration and associated with marked autonomic features). Acute migraine treatment includes NSAIDs, triptans, and in some cases antiemetics. Prophylactic treatments for frequent migraine include beta blockers, antiepileptics, and antidepressants. In pregnancy, acetaminophen is preferred for acute management, and many prophylactic agents require careful risk-benefit analysis during pregnancy and lactation. Option A (30 to 60 minute duration) is incorrect because migraine attacks typically last several hours to days. Option B (Throbbing quality) correctly represents the classic description of migraine pain. Option C (Bilateral location) is more characteristic of tension-type headache, and Option D (Not aggravated by daily activity) is inaccurate since migraine pain is often worsened by physical activity. 1. Migraines are classically unilateral, pulsatile, and worsened by physical activity. 2. Recognition of associated symptoms (photophobia, phonophobia, nausea) aids in diagnosis. 3. Differential diagnosis is essential to avoid mismanagement. Updated guidelines, including those from the American Headache Society, continue to emphasize the role of triptans and NSAIDs. Research is increasingly focusing on CGRP antagonists as a novel therapeutic option for migraine management.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "What is the physiology of cluster headache.",
    "option_a": "Imbalance neurotraumatic in trigeminal nerve",
    "option_b": "Brainstem change modulation",
    "option_c": "Ipsilateral hypothalamus in CNS",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a primary headache disorder classified under trigeminal autonomic cephalalgias. It is characterized by severe, unilateral headaches accompanied by ipsilateral autonomic symptoms. Functional neuroimaging studies have consistently demonstrated activation of the ipsilateral posterior hypothalamus during cluster headache attacks. This hypothalamic dysfunction is thought to disrupt the trigeminal-autonomic reflex, leading to the intense pain and autonomic features seen in these patients. Patients with cluster headaches experience severe unilateral pain typically around the orbital, temporal, or supraorbital regions, along with autonomic signs such as tearing, nasal congestion, and eyelid edema. The attacks exhibit a circadian pattern, often occurring at the same time each day. Diagnosis is clinical based on criteria from the International Classification of Headache Disorders. Differential diagnoses include SUNCT/SUNA (which have shorter duration attacks), paroxysmal hemicrania (which is exquisitely indomethacin-responsive), and migraine with autonomic symptoms. Neuroimaging may be used to rule out secondary causes. For acute management, high-flow oxygen and subcutaneous sumatriptan are first-line therapies. Prophylactic treatment is centered around verapamil, with lithium and corticosteroids as alternatives or transitional therapies. In pregnancy and lactation, oxygen is safe, while medications like sumatriptan and verapamil require careful risk\u2013benefit assessment and close monitoring. Option A (Imbalance neurotraumatic in trigeminal nerve) does not reflect the central mechanism implicated in cluster headache. Option B (Brainstem change modulation) is too non-specific. Option C (Ipsilateral hypothalamus in CNS) is supported by neuroimaging and is the key physiologic finding in cluster headache, making it correct. 1. Cluster headaches display a marked circadian pattern. 2. High-flow oxygen can abort attacks rapidly. 3. Functional imaging often shows hypothalamic activation during cluster attacks. Recent neuroimaging studies have reinforced the role of the hypothalamus in cluster headache pathophysiology. Current guidelines advocate oxygen and sumatriptan for acute management while emphasizing verapamil for prophylaxis, with ongoing research into neuromodulation strategies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Male patient with headache, congestion, tearing, duration 15-30 min, happened 5 times /day, always on same side (History of pain provoked by touching the face). (No PH in choices)",
    "option_a": "SUNCT",
    "option_b": "SUNA",
    "option_c": "Migraine",
    "option_d": "Cluster Headache",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "The case describes a headache syndrome in a male patient with unilateral pain, ipsilateral autonomic features (congestion, tearing), and a recurrent pattern with 15\u201330 minute duration and multiple attacks per day. This constellation of features is characteristic of a trigeminal autonomic cephalalgia, particularly cluster headache. Cluster headache is believed to result from dysfunction in the posterior hypothalamus and activation of the trigeminal-autonomic reflex. Although cluster headache is not classically defined by trigger zones, sensitization in the trigeminal system may occasionally render the area hyper-responsive to touch. The typical cluster headache attack lasts 15\u2013180 minutes, occurs multiple times per day during a cluster period, and is associated with severe unilateral pain and ipsilateral autonomic symptoms such as tearing and nasal congestion. While provocation by facial touch is more characteristic of trigeminal neuralgia, the overall clinical picture (including attack duration and autonomic signs) fits cluster headache. The diagnosis is clinical, based on the ICHD-3 criteria for cluster headache. Differential diagnoses include SUNCT/SUNA (which have much shorter attack durations, usually seconds to a few minutes), migraine (which generally lasts hours and is aggravated by activity), and trigeminal neuralgia (which typically features brief, shock-like pains without prominent autonomic symptoms). Acute management of cluster headache involves high-flow oxygen and subcutaneous sumatriptan. Prophylactically, verapamil is considered first-line, with corticosteroids or lithium used as transitional agents. In pregnancy and lactation, oxygen remains safe; however, the use of sumatriptan and verapamil must be carefully evaluated with consideration given to the risks versus benefits and in consultation with specialists. Option A (SUNCT) and Option B (SUNA) are typically characterized by very short-lasting attacks (seconds to a few minutes) rather than 15\u201330 minutes. Option C (Migraine) is usually associated with a longer duration, photophobia, and a throbbing quality, and lacks the prominent ipsilateral autonomic symptoms seen here. Option D (Cluster Headache) is the best fit given the duration, frequency, and autonomic features, even though the presence of a trigger (touching the face) is atypical but may occur due to trigeminal sensitization. 1. Cluster headaches, though less common than migraines, cause excruciating pain with a distinct circadian pattern. 2. High-flow oxygen is a rapid and effective abortive treatment. 3. While trigger zones are classic for trigeminal neuralgia, the overall clinical picture is key to diagnosis. Recent studies underscore the role of the hypothalamus in cluster headache, and current guidelines recommend oxygen and sumatriptan for acute management with verapamil as the cornerstone of prophylaxis. Ongoing trials are evaluating neuromodulatory approaches, especially for patients refractory to traditional medical therapy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "What\u2019s the mechanism of action of botox in migraine headache.",
    "option_a": "Serotonin agonist",
    "option_b": "Serotonin reuptake inhibitors",
    "option_c": "Monoamine inhibitor",
    "option_d": "glutamates inhibition",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Botulinum toxin (Botox) is used for chronic migraine prophylaxis. Its core mechanism involves preventing the release of pain-mediating neurotransmitters at the neuronal synapse by cleaving SNARE proteins. Although it affects the release of multiple substances, one of the relevant mediators in migraine is glutamate. Botox acts by cleaving SNAP-25, a key protein required for vesicle fusion and neurotransmitter release. This inhibition reduces the exocytosis of several neuropeptides such as calcitonin gene\u2010related peptide (CGRP), substance P, and glutamate. The reduction in glutamate, an excitatory neurotransmitter, helps decrease peripheral nociceptive input and may reduce central sensitization associated with chronic migraine. In patients with chronic migraine (headache on 15 or more days per month), injections of Botox in specific head and neck muscles reduce the release of neurotransmitters that amplify pain sensations. This ultimately leads to a reduction in the frequency and severity of migraine attacks. The clinical diagnosis of chronic migraine is primarily based on headache frequency and characteristics. Differential diagnoses include tension-type headache or medication overuse headache. Neuroimaging is generally reserved for atypical presentations. Botox is specifically used as a preventive measure in patients meeting chronic migraine criteria. The current guidelines recommend onabotulinumtoxinA as a preventive option in chronic migraine. It is usually considered after failure or intolerance of standard oral preventive medications. Note that its safety in pregnancy is not well established, so alternative therapies should be considered in pregnant patients. Option A (Serotonin agonist) and Option B (Serotonin reuptake inhibitors) refer to medications that modulate serotonin but do not describe Botox's mechanism. Option C (Monoamine inhibitor) does not accurately represent Botox\u2019s mode of action. Option D (glutamates inhibition) is the closest answer since one key effect of Botox is reducing glutamate release, even though its mechanism also involves other neuropeptides. 1) Botox is approved for prophylactic treatment of chronic migraine. 2) Its mechanism involves cleavage of SNAP-25 and inhibition of neurotransmitter release. 3) Although it inhibits several neurotransmitters, suppression of glutamate release is a clinically relevant effect in migraine management. Recent studies, including the PREEMPT clinical trials, have reinforced the efficacy of Botox in chronic migraine by demonstrating reductions in headache days and improvements in quality of life. Research continues to explore its multimodal mechanism, confirming that inhibition of excitatory neurotransmitters such as glutamate is a critical component.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of cluster headache what additional finding.",
    "option_a": "MRI brain show brainstem hyperintensities",
    "option_b": "PET scan show changes in diencephalon",
    "option_c": "EEG shows spike and acceleration",
    "option_d": "Trigeminal nerve hypertrophy",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a primary headache disorder characterized by severe unilateral pain and prominent autonomic symptoms. Functional neuroimaging has identified that the diencephalon\u2014particularly the posterior hypothalamus\u2014plays a central role in its pathogenesis. Activation of the posterior hypothalamus is a hallmark of cluster headache attacks. PET scans often reveal increased metabolic activity and changes in the diencephalon during an attack. This area is involved in circadian rhythm regulation and autonomic control, which correlate well with the periodicity and autonomic symptoms seen in cluster headaches. Patients with cluster headache experience excruciating unilateral periorbital pain with accompanying autonomic features such as lacrimation, nasal congestion, and sometimes Horner\u2019s syndrome. The involvement of the diencephalon explains the circadian predilection (often at night) and the systemic autonomic symptoms. While the diagnosis of cluster headache is clinical, neuroimaging, including PET scans, supports the involvement of the diencephalon. Differential diagnoses include other trigeminal autonomic cephalalgias like paroxysmal hemicrania and SUNCT/SUNA, and migraine. MRI is used to rule out secondary causes. PET scan findings, though not routine in clinical practice, highlight hypothalamic activation specific to cluster headaches. Acute management typically includes high-flow oxygen and subcutaneous or intranasal triptans. Prophylactic treatment often involves verapamil. Functional imaging research has advanced our understanding, but treatment remains largely symptomatic. In pregnant patients (rare in cluster headache cases), oxygen is safe and medications like sumatriptan may be considered if clearly indicated and after risk\u2013benefit assessment. Option A (MRI brain show brainstem hyperintensities) is not a recognized finding in cluster headache. Option B (PET scan showing changes in diencephalon) correctly identifies the functional imaging findings in cluster headache. Option C (EEG shows spike and acceleration) is irrelevant, as EEG abnormalities are not typically associated with headaches. Option D (Trigeminal nerve hypertrophy) is not observed in cluster headaches. 1) Cluster headache is strongly associated with hypothalamic (diencephalic) activation on PET imaging. 2) The characteristic circadian pattern of cluster headache is linked to diencephalic dysfunction. 3) High-flow oxygen remains a first-line acute treatment in cluster headache. Updated neuroimaging research has consistently shown posterior hypothalamic activation during cluster headache attacks, reinforcing its role in pathogenesis. This evidence underpins current therapeutic strategies focused on modulating hypothalamic function.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Headache out of blue since 3 month.",
    "option_a": "NDPH",
    "option_b": "SUNA",
    "option_c": "HC",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "New Daily Persistent Headache (NDPH) is a primary headache syndrome characterized by a sudden onset of a persistent daily headache that continues without significant remission for at least three months. The exact underlying mechanisms of NDPH remain unclear. Hypotheses include a possible trigger such as an infection or stress event that sets off a persistent activation of pain pathways. Unlike migraine, NDPH does not typically show a fluctuating pattern and may share some features with both migraine and tension-type headaches. Patients with NDPH describe the abrupt onset of headache on a particular day \u2013 often remembered by the patient \u2013 which then becomes unremitting. The headache does not remit or significantly improve over time, distinguishing it from other headache types. The diagnosis is made primarily on clinical history. Differential diagnoses include chronic migraine (which generally has a history of episodic attacks with some remissions), chronic tension-type headache, and secondary headaches. Neuroimaging should be performed to rule out structural causes. Detailed history is vital for differentiating NDPH from headache disorders with episodic patterns. Management of NDPH is challenging. First-line treatment is symptomatic management often using analgesics and preventive measures. Behavioral therapies and non-pharmacological strategies are emphasized because the response to medications is often limited. In pregnant patients, treatment is even more cautious; acetaminophen (paracetamol) is preferred, and medication overuse should be avoided. Option A (NDPH) matches the description of a headache that appears \u201cout of blue\u201d and persists daily for three months. Option B (SUNA) is characterized by short, brief attacks with cranial autonomic symptoms, not a continuous daily headache. Option C (HC or Hemicrania continua) typically presents as a continuous unilateral headache responsive to indomethacin and has a distinct clinical profile. 1) NDPH has a clear, abrupt onset and then persists without significant remission. 2) A detailed headache history is crucial to differentiate NDPH from migraines and tension-type headaches. 3) Treatment is mainly symptomatic and focused on avoiding medication overuse. Recent studies have highlighted the refractory nature of NDPH to standard migraine therapies, emphasizing the need for individualized management plans. Ongoing research aims to better understand the pathophysiology to develop more targeted treatments.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant came with severe migraine attack, similar to her previous migraine attacks, appropriate management.",
    "option_a": "Paracetamol",
    "option_b": "Sumatriptan",
    "option_c": "Opioid",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine is a common primary headache disorder, and managing acute attacks in pregnancy requires careful selection of medications to minimize fetal risk. Paracetamol is widely recognized as a safe and effective first-line option for pain relief during pregnancy. Migraine is thought to involve activation of the trigeminovascular system, leading to the release of vasoactive substances that cause vasodilation and inflammation. In pregnant patients, treatment choices must account for both maternal and fetal well-being. Paracetamol acts centrally to inhibit prostaglandin synthesis, thereby providing analgesic effects with minimal adverse effects. Pregnant patients with a history of migraine often experience similar patterns of headache during pregnancy. The safety profile of paracetamol makes it the preferred treatment for acute migraine attacks during pregnancy, particularly in women with a history of uncomplicated migrainous episodes. Diagnosis is clinical based on the patient's migraine history. Differential diagnoses may include tension-type headache and other primary headaches. Imaging and extensive work-up are generally not indicated unless there are atypical features or \u201cred flags\u201d. Based on current guidelines, paracetamol (acetaminophen) is recommended as the first-line treatment for acute migraine attacks during pregnancy due to its strong safety record. If paracetamol is ineffective, additional agents such as certain antiemetics (e.g., metoclopramide) or even sumatriptan may be considered after a careful risk\u2013benefit analysis. Opioids are generally avoided due to risks of dependency and adverse fetal effects. Lactation considerations are similar, with paracetamol being safe during breastfeeding. Option A (Paracetamol) is the safest and recommended first-line option for migraine treatment during pregnancy. Option B (Sumatriptan) is considered relatively safe but is generally reserved for refractory cases. Option C (Opioid) is not recommended due to potential maternal dependence and fetal/neonatal risks. 1) Paracetamol is the cornerstone of acute migraine management in pregnancy. 2) Nonpharmacological methods and a stepwise approach are essential in managing migraine during pregnancy. 3) Escalation to triptans is acceptable if the initial treatment is ineffective, but opioids should be avoided. Recent guidelines and systematic reviews continue to support the use of paracetamol as the first-line therapy in pregnancy. While sumatriptan has emerging evidence of safety in pregnancy, paracetamol remains preferred due to its well-established safety profile and minimal risk to the fetus, a point underscored by both ACOG and other international bodies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario with a post-partum lady with severe post-partum headache and weakness Angio of RCVS with plain CT showing convex SAH what is the diagnosis:",
    "option_a": "Rcvs",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Reversible Cerebral Vasoconstriction Syndrome (RCVS) is a clinical\u2013radiological syndrome characterized by thunderclap headaches with reversible multifocal arterial vasoconstriction. In the postpartum period, hormonal fluctuations and hemodynamic stress predispose to RCVS. RCVS is thought to result from transient dysregulation of cerebral arterial tone. In the postpartum setting, a sudden change in circulating hormones and catecholamine surges may lead to segmental vasoconstriction. This vasospasm can cause small vessel rupture, leading to a convexity subarachnoid hemorrhage (SAH) on imaging. Patients typically present with sudden, severe (thunderclap) headaches, sometimes associated with focal neurological deficits (as noted here with weakness). The postpartum period is a recognized risk factor. CT may reveal a localized (convex) SAH, and angiography typically shows a 'beading' pattern of the vasculature due to alternating areas of constriction and dilation. Diagnosis is based on clinical presentation, non-contrast CT (which may show convex SAH), and confirmatory vascular imaging (CTA/MRA or conventional angiography) demonstrating segmental arterial narrowing. Differential diagnoses include aneurysmal SAH (which usually involves the basal cisterns), cerebral vasculitis, and postpartum preeclampsia/eclampsia. Management typically involves supportive care and calcium channel blockers (such as nimodipine) to reduce vasospasm, along with avoidance of triggers (e.g., vasoactive substances). In postpartum patients, it is important to consider breastfeeding safety when prescribing medications. Close monitoring and follow-up imaging are recommended. Severe cases may require hospitalization for blood pressure control and neurological observation. Option A (RCVS) is correct because the clinical scenario (postpartum, severe headache, convex SAH on CT, and angiographic findings) is classic for RCVS. The other options are absent and hence not applicable. 1. The postpartum period is a high-risk time for RCVS due to hormonal and hemodynamic shifts. 2. The presence of convex SAH (rather than the typical cisternal SAH seen with aneurysms) is a radiologic clue to RCVS. 3. Reversibility of the angiographic changes is a key diagnostic feature. Recent guidelines emphasize the importance of recognizing RCVS early to prevent complications. Studies have validated the use of calcium channel blockers and supportive care. Ongoing research focuses on the pathophysiologic mechanisms and optimal management strategies in postpartum women.",
    "exam_year": "2020",
    "exam_type": "Part II",
    "image_url": "https://drive.google.com/file/d/1IKFt4am7GrC92CefgZJ6Qj2sNVCtVfYN/preview"
  }
]